FDG PET/MR联合低剂量胸部CT用于局部晚期乳腺癌初始分期的成本效益
本研究通过决策分析模型比较FDG PET/MR联合低剂量胸部CT与常规多模态成像在新诊断浸润性导管乳腺癌患者中的成本效益。在 presumed III期患者中，PET/MR策略将模型推导的分期准确率从70%提高至97%，增量成本效益比约为每例正确分期患者3000美元。在高风险IIB期患者中，成本效益对转移患病率更敏感。
要点
- PET/MR联合低剂量胸部CT在 presumed III期乳腺癌中分期准确率更高（97% vs 70%）
- 增量成本效益比约3000美元/例正确分期，价格假设稳健
- 高风险IIB期患者的成本效益更依赖转移患病率
局限性
- 研究基于决策分析模型，非真实临床队列验证
- 模型输入依赖已发表的诊断性能数据和报销代理值，可能存在异质性
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
英文原文（摘要）· 点击展开
OBJECTIVE: To evaluate the cost-effectiveness of an integrated fluorodeoxyglucose (FDG) PET/MR-based staging strategy supplemented with low-dose chest CT compared with guideline-based conventional imaging in patients with newly diagnosed invasive ductal breast cancer.
METHODS: A decision-analytic model was developed to compare conventional multimodality staging (contrast-enhanced CT, bone scintigraphy, and breast MR) with an integrated FDG PET/MR-based staging strategy supplemented with low-dose chest CT. The primary analysis focused on patients with presumed clinical stage III disease; a secondary analysis examined high-risk stage IIB patients. Model inputs included published diagnostic performance data and standardized reimbursement proxies. Outcomes included cost per patient correctly staged for distant metastases, incremental cost-effectiveness ratios, and a supplementary short-term quality-adjusted life-year analysis. Deterministic and probabilistic sensitivity analyses were performed.
RESULTS: In presumed stage III disease, the PET/MR-based strategy improved model-derived staging accuracy compared with conventional imaging (97% [95% uncertainty interval {UI}: 94%-99%] versus 70% [95% UI: 64%-76%]) and reduced false-positive findings. Although associated with higher upfront imaging costs, the incremental cost-effectiveness ratio was approximately $3,000 per additional patient correctly staged (95% UI: $1,500-$6,500). Results remained robust across wide pricing assumptions. In high-risk stage IIB patients, cost-effectiveness was more sensitive to metastatic prevalence. The short-term quality-adjusted life-year analysis demonstrated modest short-term utility gains favoring PET/MR.
DISCUSSION: Integrated FDG PET/MR with adjunct low-dose chest CT is economically attractive in patients with presumed locally advanced breast cancer. Selective implementation in high-risk populations may improve diagnostic efficiency while mitigating downstream costs associated with fragmented imaging pathways.
引用
- Asmundo L, Blandino AA, Quiros E, et al. Cost-Effectiveness of Integrated Fluorodeoxyglucose PET/MR With Low-Dose Chest CT for Initial Staging of Locally Advanced Breast Cancer. J Am Coll Radiol. 2026. PMID: 42191008. doi:10.1016/j.jacr.2026.05.019
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。